Laboratory measurement of the direct oral anticoagulants
Key result
Direct oral anticoagulant levels can be quantified using specific assays like Hemoclot and calibrated chromogenic anti-FXa assays, though traditional coagulation tests remain useful.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports targeted DOAC quantification with specific assays when indicated; leaves open prospective validation of clinical thresholds.
Key Points
- The aim is to investigate the need for and methods of measuring direct oral anticoagulants (DOACs) in clinical settings.
- Evaluated the effectiveness of traditional coagulation tests for DOAC measurement.
- Assessed the use of hemoclot and ecarin-based assays for dabigatran, and calibrated chromogenic anti-FXa assays for rivaroxaban, apixaban, and edoxaban.
- Traditional coagulation tests provide limited sensitivity and specificity for DOAC measurement.
- Hemoclot and ecarin-based assays effectively quantify dabigatran levels; calibrated chromogenic assays effectively measure rivaroxaban, apixaban, and edoxaban.
- These specialized assays are not widely available, limiting widespread clinical implementation.
PICO
P
Population
Thromboembolism
E
Exposure / Comparator
Direct oral anticoagulants (DOACs)
While DOACs do not require routine monitoring, specific assays such as Hemoclot, ecarin-based, and calibrated chromogenic anti-FXa assays are suitable for quantifying drug levels when clinically necessary.
Limitations
- Traditional coagulation tests lack analytical sensitivity and specificity
- Specific assays for quantifying DOAC levels are not yet widely available
Cite This Study
Dale et al. (2015) conducted a review in Thromboembolism. Direct oral anticoagulants (DOACs) was evaluated. Direct oral anticoagulant levels can be quantified using specific assays like Hemoclot and calibrated chromogenic anti-FXa assays, though traditional coagulation tests remain useful.